Chemotherapy Induced Neutropenia - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

107 Pages (PDF)




Chemotherapy Induced Neutropenia - Pipeline Review, H1 2014

Summary

Global Markets Directs, Chemotherapy Induced Neutropenia - Pipeline Review, H1 2014, provides an overview of the Chemotherapy Induced Neutropenias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Neutropenia Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11
Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12
Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13
Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 16
Chemotherapy Induced Neutropenia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chemotherapy Induced Neutropenia - Products under Development by Companies 21
Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 22
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 23
Amgen Inc. 23
Reliance Life Sciences Pvt. Ltd. 24
Richter Gedeon Nyrt. 25
Teva Pharmaceutical Industries Limited 26
Sandoz Inc. 27
Zosano Pharma, Inc. 28
Jiangsu Hengrui Medicine Co., Ltd. 29
Cellerant Therapeutics, Inc. 30
Bolder Biotechnology, Inc. 31
Welichem Biotech Inc. 32
Bio-Ker s.r.l 33
PharmaEssentia Corporation 34
Pfenex Inc. 35
Mycenax Biotech Inc. 36
XBiotech USA, Inc. 37
Tarix Pharmaceuticals LTD. 38
Hanmi Pharmaceuticals, Co. Ltd. 39
Generon (Shanghai) Corporation Ltd. 40
Io Therapeutics, Inc. 41
Biogenomics Limited 42
Myelo Therapeutics GmbH 43
Dong-A Socio Holdings Co Ltd 44
Chemotherapy Induced Neutropenia - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
balugrastim - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pegfilgrastim biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
lipegfilgrastim - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
balugrastim - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pegfilgrastim - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
pegfilgrastim - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
filgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
pegfilgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
HM-10460A - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
F-627 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
romyelocel-L - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
F-627 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
BK-0026 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GW-003 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
filgrastim biosimilar - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pegfilgrastim - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
WBI-2100 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PanCyte - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
BBT-015 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
BBT-018 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
BBT-007 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IRX-4310 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
filgrastim - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
filgrastim - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
pegfilgrastim - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TheraPhil - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Myelo-001 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
pegfilgrastim biosimilar - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
filgrastim - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
filgrastim - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Chemotherapy Induced Neutropenia - Recent Pipeline Updates 93
Chemotherapy Induced Neutropenia - Dormant Projects 98
Chemotherapy Induced Neutropenia - Discontinued Products 99
Chemotherapy Induced Neutropenia - Product Development Milestones 100
Featured News & Press Releases 100
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 100
Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 100
Nov 18, 2013: Teva Announces Update on review status of balugrastim by the U.S. Food and Drug Administration 101
Nov 18, 2013: Teva announces Launch of LONQUEX Injection 101
Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 103
Jun 27, 2013: Kyowa Hakko Kirin Submits Application For Approval In Japan For Sustained-duration G-CSF Product 103
Jun 03, 2013: Teva's Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 104
Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 104
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 105
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107
Amgen Inc.
Reliance Life Sciences Pvt. Ltd.
Richter Gedeon Nyrt.
Teva Pharmaceutical Industries Limited
Sandoz Inc.
Zosano Pharma, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Cellerant Therapeutics, Inc.
Bolder Biotechnology, Inc.
Welichem Biotech Inc.
Bio-Ker s.r.l
PharmaEssentia Corporation
Pfenex Inc.
Mycenax Biotech Inc.
XBiotech USA, Inc.
Tarix Pharmaceuticals LTD.
Hanmi Pharmaceuticals, Co. Ltd.
Generon (Shanghai) Corporation Ltd.
Io Therapeutics, Inc.
Biogenomics Limited
Myelo Therapeutics GmbH
Dong-A Socio Holdings Co Ltd				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement